进展期非小细胞肺癌的维持治疗

Maintenance therapy in advanced non-small cell lung cancer

4-6周期联合化疗达到“化疗疗效平台”后，进一步维持治疗能否改善进展期非小细胞肺癌患者的生存，是目前临床关注的热点。随着一些具有良好耐受性的化疗药物和分子靶向药物的介入，一些临床研究已经证实，在疾病控制的患者，维持治疗能带来进一步的临床获益，主要表现为无进展生存期的延长，并有改善总生存的趋势。

Following four to six cycles of chemotherapy for patients with non-small cell lung cancer （NSCLC）. Chemotherapy efficacy plateau has been achieved. Whether maintenance therapy can improve these patient＇ s survival becomes a new focus now. Several randomized clinical trials have demonstrated that maintenance therapy with well-tolerated chemotherapeutic or molecular-targeted agents may benefit patients with advanced NSCLC who experience a response or disease stabilization after chemotherapy, which include prolonging progression-free survival and attering total survival.